EGFR and neoplasm: Cetuximab, a monoclonal antibody targeting EGFR conjugated with radionuclides showed a therapeutic efficacy in a broad set of tumor types as monotherapy or combination therapy with chemo- or radiotherapy [4,7,8,9,10,11,12,13,14].